Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Shares Sold by TD Asset Management Inc

Key Points

• TD Asset Management Inc. reduced its stake in Structure Therapeutics by 50.8%, owning 43,686 shares valued at approximately $756,000 after selling 45,196 shares in the first quarter.
• Several institutional investors, including Janus Henderson Group PLC and Deep Track Capital LP, increased their stakes in Structure Therapeutics during the fourth quarter, indicating ongoing interest among hedge funds.
• Structure Therapeutics reported a quarterly EPS of ($0.27), missing analysts' expectations of ($0.24) and projecting a forecasted EPS of –0.82 for the current fiscal year.

TD Asset Management Inc lessened its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 50.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,686 shares of the company's stock after selling 45,196 shares during the quarter. TD Asset Management Inc owned about 0.08% of Structure Therapeutics worth $756,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Janus Henderson Group PLC increased its stake in shares of Structure Therapeutics by 5.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock valued at $112,816,000 after acquiring an additional 203,010 shares during the period. Deep Track Capital LP increased its stake in shares of Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after acquiring an additional 1,579,492 shares during the period. Vestal Point Capital LP increased its stake in shares of Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after acquiring an additional 575,000 shares during the period. Capital International Investors grew its position in Structure Therapeutics by 6.8% in the fourth quarter. Capital International Investors now owns 1,619,081 shares of the company's stock worth $43,909,000 after buying an additional 103,059 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its position in Structure Therapeutics by 29.4% in the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock worth $38,512,000 after buying an additional 322,601 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $16.78 on Tuesday. The company has a 50 day moving average price of $20.28 and a 200 day moving average price of $22.08. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $13.22 and a 52 week high of $45.37. The firm has a market capitalization of $962.22 million, a price-to-earnings ratio of -19.29 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on GPCR shares. JMP Securities restated a "market outperform" rating and issued a $89.00 price target on shares of Structure Therapeutics in a research report on Monday, June 23rd. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, June 23rd. Citigroup started coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target on the stock. Finally, HC Wainwright decreased their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics currently has an average rating of "Buy" and a consensus target price of $76.17.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.